knowledg
organ
defend
organ
accumul
biolog
scienc
progress
current
concept
innat
adapt
defens
mechan
use
describ
complex
multilay
biolog
conflict
invad
host
organ
defensin
innat
defens
molecul
ancient
origin
trace
back
organ
approxim
million
year
ago
erwin
davidson
phoenix
et
al
zhu
gao
histori
discoveri
human
defensin
review
elsewher
boman
lehrer
phoenix
et
al
review
focu
studi
contribut
practic
applic
human
defensin
antivir
defensin
known
antimicrobi
function
innat
defens
molecul
hancock
diamond
howev
regardless
effect
certain
human
pathogen
differ
experiment
set
infect
caus
pathogen
fulli
clear
without
adapt
immun
system
know
much
abil
modifi
defend
specif
pathogen
mani
bacteri
viral
diseas
effect
elimin
vaccin
therapeut
antibodi
attest
compet
make
use
adapt
immun
system
innat
immun
system
har
target
specif
pathogen
although
attempt
made
wang
et
al
park
et
al
woo
et
al
due
rel
nonspecif
target
defensin
compar
adapt
arm
antivir
applic
defensin
conceptu
ideal
defens
differ
viral
infect
although
vaccin
consid
best
prophylact
measur
microbi
pathogen
develop
vaccin
certain
virus
human
immunodefici
viru
hiv
respiratori
syncyti
viru
rsv
dengu
viru
denv
challeng
defi
decad
effort
vannic
et
al
robert
et
al
pollara
et
al
moreov
although
dengu
viru
vaccin
approv
recent
still
issu
risk
benefit
balanc
due
complex
diseas
mechan
involv
crosssubtyp
immun
respons
ferguson
et
al
scott
case
influenza
viru
iav
univers
vaccin
broadli
neutral
antibodi
particular
interest
recent
year
address
problem
annual
vaccin
updat
due
ceaseless
antigen
chang
viru
carrat
flahault
pica
pales
krammer
et
al
problem
could
solv
antigen
variationindepend
univers
activ
defensin
howev
regardless
presenc
defensin
human
bodi
report
antivir
effect
defensin
virus
hiv
chang
et
al
mackewicz
et
al
quinonesmateu
et
al
chang
et
al
sun
et
al
wu
et
al
weinberg
et
al
furci
et
al
saitoh
et
al
herrera
et
al
iav
daher
et
al
leikina
et
al
hartshorn
et
al
salvator
et
al
tecl
et
al
white
et
al
doss
et
al
mahanonda
et
al
individu
succumb
virus
review
provid
brief
overview
defensin
discuss
feasibl
use
human
defensin
variou
viral
infect
discuss
need
strateg
approach
base
conceptu
framework
potenti
applic
defensin
antivir
defens
defensin
belong
categori
antimicrobi
peptid
amp
nonenzymat
inhibitori
effect
broad
spectrum
microorgan
need
selfdefens
univers
amp
univers
present
organ
one
form
anoth
detail
review
amp
defensin
boman
ganz
lehrer
klotman
chang
lehrer
lu
jarczak
et
al
phoenix
et
al
wilson
et
al
wien
et
al
wilson
et
al
databas
dedic
amp
phoenix
et
al
three
differ
type
defensin
includ
identifi
thu
far
first
isol
earli
given
name
human
neutrophil
peptid
hnp
ganz
et
al
term
defensin
first
use
lehrer
replac
earlier
name
mammal
express
type
defensin
although
mice
commonli
use
anim
model
express
mous
neutrophil
eisenhau
lehrer
rel
broadli
express
among
mammal
express
nonhuman
primat
garcia
et
al
defensin
character
amphipath
peptid
net
posit
charg
three
pair
disulfidebondform
cystein
fig
amphipath
presenc
disulfid
bond
posit
charg
defensin
appear
import
function
defensin
individu
defensin
exhibit
differenti
effect
variou
target
ganz
one
direct
irrevers
effect
defensin
target
organ
membran
disrupt
lehrer
et
al
defensin
antivir
effect
envelop
nonenvelop
virus
membran
disrupt
presum
one
antivir
mechan
defensin
envelop
virus
similar
antibacteri
mechan
shown
directli
daher
et
al
antivir
mechan
defensin
appear
base
specif
bind
certain
viral
protein
nonspecif
lectinlik
bind
envelop
glycoprotein
virus
smith
nemerow
nguyen
et
al
smith
et
al
gounder
et
al
flatt
et
al
teng
et
al
given
mechan
inhibitori
effect
defensin
attribut
block
fundament
interact
influenza
glycoprotein
hemagglutinin
cellular
receptor
sialic
acid
leikina
et
al
specif
lectinlik
bind
defensin
cellular
receptor
also
interfer
cell
signal
requir
success
replic
virus
demirkhanyan
et
al
addit
respect
effect
defensin
viral
entri
replic
appear
particip
enhanc
adapt
antivir
respons
attract
antigenpres
cell
apc
site
infect
stimul
ryan
et
al
saitoh
et
al
human
express
harbor
pseudogen
six
human
had
abbrevi
wilson
et
al
had
small
peptid
approxim
amino
acid
length
process
prepropeptid
contain
aminotermin
signal
sequenc
anion
propiec
carboxytermin
matur
peptid
express
human
hbd
observ
human
although
comput
search
human
genom
identifi
least
gene
schutt
et
al
hbd
also
synthes
prepropeptid
matur
form
approxim
amino
acid
length
garcia
et
al
had
hbd
structur
conserv
spite
signific
differ
genet
sequenc
hoover
et
al
szyk
et
al
had
primarili
express
constitut
granulocyt
intestin
paneth
cell
major
express
site
hbd
epitheli
cell
variou
organ
although
had
studi
four
hbd
extens
studi
constitut
express
epitheli
cell
express
also
induc
variou
human
peripher
blood
mononuclear
cell
envelop
virus
ryan
et
al
virus
bacteria
microbi
product
proinflammatori
cytokin
tumornecrosi
factor
tnf
induc
express
variou
cell
yin
et
al
wilson
et
al
bacteria
also
induc
express
menendez
brett
finlay
tabl
antivir
activ
human
defensin
studi
variou
virus
summar
tabl
herp
simplex
viru
hsv
one
first
virus
studi
antivir
activ
had
show
highest
suscept
had
among
virus
test
daher
et
al
hiv
studi
target
defensin
mechan
antivir
effect
defensin
depend
type
viru
straightforward
antibacteri
mechan
direct
irrevers
inactiv
membran
disrupt
lehrer
et
al
recogn
earli
presenc
serum
serum
albumin
affect
antivir
effect
defensin
vitro
daher
et
al
chang
et
al
therefor
physiolog
signific
antivir
effect
defensin
remain
unclear
even
suggest
antivir
effect
defensin
may
side
effect
antibacteri
effect
peptid
boman
difficult
determin
whether
defensin
critic
antivir
defens
human
extrapol
studi
use
mous
model
murin
defici
mous
model
show
murin
counterpart
particip
protect
mice
influenza
infect
via
mechan
inhibit
viral
replic
ryan
et
al
anoth
studi
use
mous
model
defici
activ
small
intestin
show
paneth
cell
murin
counterpart
protect
mice
oral
infect
mous
adenoviru
howev
despit
vitro
neutral
activ
paneth
cell
absenc
effect
kinet
magnitud
dissemin
brain
although
delay
protect
neutral
antibodi
respons
gounder
et
al
studi
suggest
inhibit
viru
replic
defensin
vitro
might
necessarili
relev
vivo
respect
antivir
applic
defensin
understand
enhanc
adapt
immun
defensin
respons
infect
virus
appear
crucial
mani
vitro
studi
tabl
shown
defensin
antivir
activ
first
question
applic
defensin
antivir
defens
may
would
better
use
prophylact
therapeut
constitut
express
had
hbd
natur
prophylact
measur
suffici
fulli
protect
us
viral
infect
mani
virus
report
induc
express
defensin
proud
et
al
wiehler
proud
kota
et
al
bustosarriaga
et
al
ryan
et
al
surasombatpattana
et
al
ju
et
al
castanedasanchez
et
al
regardless
abil
induc
defensin
block
infect
virus
question
whether
defensin
either
constitut
viru
infectioninduc
would
help
clear
viru
sempl
et
al
show
enhanc
product
respons
polyinosin
polycytidyl
acid
poli
c
surrog
viral
doublestrand
rna
human
mous
primari
cell
find
recapitul
mice
express
transgen
encod
shown
use
murin
counterpart
receptor
mice
rohrl
et
al
result
suggest
excess
amount
defensin
express
may
signific
effect
respons
viral
infect
closest
exampl
prophylact
overexpress
defensin
report
li
et
al
show
murin
defensinoverexpress
mice
protect
lethal
iav
infect
studi
intramuscularli
inject
mice
liposomeencapsul
overexpress
construct
h
prior
iav
challeng
infect
experi
reduct
viral
lung
titer
mice
inject
overexpress
construct
observ
result
might
consid
proof
principl
suggest
prophylact
administ
excess
amount
relev
human
defensin
may
abl
similarli
reduc
viral
titer
human
infect
viru
howev
advantag
disadvantag
continu
suppli
addit
defensin
human
care
analyz
high
concentr
induc
cytotox
wencker
brantli
although
high
concentr
hbd
appear
cytotox
effect
vitro
nishimura
et
al
studi
copi
number
variat
hbd
gene
suggest
higher
copi
number
hbd
gene
thu
higher
express
hbd
associ
diseas
psoriasi
machado
ottolini
human
defensin
also
effect
tumor
microenviron
promot
repress
tumor
growth
suarezcarmona
et
al
potenti
enhanc
certain
viral
infect
rapista
et
al
inhibit
other
rule
clearli
risk
continu
suppli
excess
defensin
anoth
potenti
concern
regard
continu
suppli
excess
amount
defensin
gener
multipl
resist
microorgan
defensin
consid
difficulti
develop
resist
greatest
advantag
use
amp
defensin
reason
microb
need
redesign
membran
lipid
composit
develop
resist
amp
mangoni
et
al
howev
sinc
antivir
activ
defensin
involv
mechan
direct
irrevers
disrupt
viral
membran
escap
origin
target
virus
antivir
effect
defensin
rule
shown
bacteri
resist
amp
could
develop
continu
expos
amp
perron
et
al
howev
reallif
infect
mobil
adapt
arm
immun
system
target
pathogen
like
occur
earlier
develop
resist
defensin
target
pathogen
evolutionari
longev
defensin
may
proof
rate
adjuv
activ
defensin
might
affect
sinc
involv
host
cell
appar
continu
suppli
certain
defensin
prevent
infect
certain
target
virus
requir
thorough
analysi
ramif
separ
whether
vitro
efficaci
approach
could
recapitul
vivo
question
may
prove
challeng
answer
whether
prophylact
applic
defensin
continu
suppli
serv
oneshot
vaccin
case
adapt
defens
hitandrun
therapeut
applic
defensin
might
avoid
problem
associ
continu
suppli
howev
whether
advantag
applic
defensin
therapeut
measur
viru
anoth
question
may
extrapol
relev
vivo
studi
use
anim
model
defensindefici
mous
model
ryan
et
al
gounder
et
al
similar
prophylact
model
sinc
allow
presenc
absenc
defensin
time
target
viru
infect
studi
furthermor
model
inhibit
viral
infect
observ
vitro
recapitul
vivo
truli
therapeut
extern
artifici
suppli
defensin
abl
reduc
replic
target
viru
observ
vitro
pseudomona
aeruginosa
infect
model
burnwound
mice
park
et
al
local
transfer
allogen
cell
infect
newcastl
diseas
viru
vector
use
effect
therapeut
applic
other
also
show
feasibl
adenovirusmedi
human
defensin
gene
deliveri
antibacteri
therapi
moon
lim
found
report
overexpress
human
defensin
therapeut
intervent
method
viral
infect
anim
model
excess
suppli
therapeut
defensin
deriv
independ
eukaryot
cell
might
anoth
approach
chemic
synthesi
human
defensin
raj
et
al
kluver
et
al
wu
et
al
heapi
et
al
vernieri
et
al
purif
bacteri
express
human
defensin
xu
et
al
report
disulfid
bond
molecular
structur
defensin
appear
critic
antibacteri
function
mandal
nagaraj
hoover
et
al
de
leeuw
et
al
sharadadevi
nagaraj
cytotox
effect
kluver
et
al
affect
antivir
host
cellmedi
activ
chemotact
activ
immatur
dendrit
cell
dc
wu
et
al
antcheva
et
al
fold
peptid
issu
case
chemic
bacteri
synthes
sinc
proseg
unprocess
defensin
shown
impact
fold
wu
et
al
affect
antigen
molecul
kurosawa
et
al
preserv
nativ
form
human
defensin
either
chemic
synthes
bacteri
express
may
crucial
prevent
potenti
unnecessari
immunolog
respons
human
bodi
recogn
extern
suppli
defensin
foreign
molecul
scant
exampl
vivo
applic
excess
amount
human
defensin
produc
bacteria
chemic
synthes
antivir
defens
one
studi
wang
et
al
use
murin
model
vagin
hsv
infect
wang
et
al
observ
chemic
synthes
treat
either
prophylact
h
prior
infect
therapeut
h
postinfect
reduc
viral
titer
also
exampl
use
nonhuman
defensin
mous
model
brandt
et
al
wohlfordlenan
et
al
one
exampl
evalu
synthet
murin
model
kerat
brandt
et
al
experi
applic
synthet
defensin
infect
reduc
viral
titer
infect
suggest
ineffect
approach
therapeut
measur
clear
whether
lack
therapeut
effect
nonhuman
primat
defensin
due
lack
murin
ortholog
could
result
lack
cellular
receptormedi
adjuvantlik
activ
jiang
et
al
use
bacteri
express
recombin
test
protect
mice
lethal
infect
iav
treatment
mice
began
h
postinfect
perform
per
day
three
week
protect
observ
dosedepend
viral
titer
bronchoalveolar
lavag
fluid
reduc
mgkgday
tail
vein
inject
provid
protect
although
block
viru
bind
entri
step
rather
subsequ
stage
ongo
infect
vitro
enhanc
virusinduc
express
dosedepend
manner
downregul
virusinduc
express
vivo
promot
differenti
cell
cell
activ
cytotox
tlymphocyt
natur
killer
nk
cell
watford
et
al
play
import
role
remov
virusinfect
cell
appear
inhibit
iav
entri
also
modul
cellmedi
adapt
innat
immun
respons
result
vivo
therapeut
efficaci
extern
administ
defensin
lemessuri
et
al
also
use
purifi
mous
model
iav
infect
lemessuri
et
al
concurr
intranas
administr
infect
iav
reduc
viral
titer
increas
express
question
whether
mous
model
studi
translat
human
least
one
defensin
shown
interchang
human
counterpart
respect
chemokin
receptor
usag
rohrl
et
al
clear
need
studi
realiz
therapeut
applic
defensin
antivir
defens
current
known
consid
direct
futur
emphasi
elabor
murin
model
defensin
gene
deliverymedi
temporari
overexpress
construct
exagger
natur
process
elimin
mani
unknown
associ
applic
defensin
deriv
independ
eukaryot
cell
elabor
translat
murin
model
eukaryot
cellindepend
deriv
human
defensin
human
two
approach
expect
complement
asid
econom
consider
discuss
formid
amount
work
need
realiz
applic
human
defensin
antivir
daunt
basic
research
applic
human
defensin
antivir
toward
specif
target
virus
would
acceler
realiz
goal
arbitrarili
name
four
rna
virus
might
worth
direct
effort
hiv
iav
rsv
denv
sever
virus
studi
target
antivir
activ
defensin
tabl
like
avail
model
statu
popular
statu
viru
appear
hiv
iav
popular
model
full
understand
virus
still
defi
us
despit
mountain
research
data
addit
hiv
iav
chosen
rsv
denv
potenti
target
worth
focus
difficulti
develop
broadli
effect
vaccin
virus
decad
effort
might
justifi
explor
virus
target
antivir
applic
defensin
carrat
flahault
vannic
et
al
ferguson
et
al
park
et
al
robert
et
al
pollara
et
al
howev
sinc
studi
antivir
effect
human
defensin
rsv
denv
scarc
discuss
matter
larg
extrapol
potenti
relat
studi
requir
studi
multipl
antivir
mechan
human
defensin
differ
mechan
applic
differ
virus
antivir
mechan
produc
reduct
viru
infect
conceptu
appli
therapeut
measur
one
mechan
heparinheparan
sulfat
proteoglycan
hspg
bind
activ
defensin
inhibit
viral
bind
entri
cell
defensin
posit
charg
lectinlik
glycanbind
activ
hazrati
et
al
lehrer
et
al
seo
et
al
de
paula
et
al
herrera
et
al
sever
envelop
virus
includ
hiv
rsv
denv
known
bind
negativelycharg
hspg
zhu
et
al
hazrati
et
al
show
vitro
studi
had
hbd
bind
either
glycoprotein
b
gb
heparan
sulfat
inhibit
hsv
show
mous
model
lethal
vagin
hsv
infect
pretreat
chemic
synthes
increas
surviv
rate
infect
mice
bound
gb
heparan
sulfat
high
affin
vitro
although
vivo
studi
use
mous
model
conduct
might
extrapol
defensin
effect
vitro
realiti
type
treatment
would
mostli
given
therapeut
measur
rather
pretreat
wang
et
al
show
therapeut
efficaci
similar
model
howev
studi
use
defensin
higher
affin
hspg
lower
affin
viral
glycoprotein
might
inform
consid
broader
gener
hspg
individu
viral
protein
studi
use
hspgbind
virus
hiv
rsv
denv
would
also
help
determin
therapeut
potenti
human
defensin
virus
studi
show
posit
charg
ctermin
region
chemokin
bound
hspg
exhibit
antivir
activ
denv
hsv
rsv
vanheul
et
al
result
encourag
studi
antivir
activ
posit
charg
human
defensin
similar
context
insepar
approach
applic
human
defensin
adjuvantlik
activ
defensin
adjuvantlik
activ
defensin
involv
recruit
host
innat
adapt
immun
cell
site
infect
activ
add
anoth
layer
inhibitori
activ
defensin
addit
block
viral
entri
ie
bind
hspg
andor
intracellular
replic
shown
act
directli
immatur
dc
endogen
ligand
tolllik
receptor
induc
upregul
costimulatori
molecul
dc
matur
link
innat
adapt
immun
respons
biragyn
et
al
adjuvantlik
function
murin
model
influenza
vaccin
also
shown
vemula
et
al
although
find
mainli
base
studi
use
murin
model
murin
defensin
report
show
murin
ortholog
chemotact
human
cell
well
murin
cell
rohrl
et
al
inde
mohan
et
al
show
adjuvantlik
effect
immun
respons
antigen
hiv
mous
model
find
suggest
human
defensin
may
adjuvantlik
activ
human
similar
observ
murin
defensin
experi
show
vivo
reduct
viral
titer
due
extern
suppli
overexpress
defensin
jiang
et
al
wang
et
al
li
et
al
lemessuri
et
al
either
therapeut
prophylact
rare
even
result
experi
due
natur
vivo
experiment
interpret
straightforwardli
experi
difficult
determin
whether
reduct
due
direct
effect
viru
replic
indirect
effect
host
interferon
product
sempl
et
al
enhanc
adapt
arm
immun
system
attract
memori
cell
macrophag
monocyt
dendrit
cell
bind
yang
et
al
rohrl
et
al
ultim
determin
part
play
larger
role
eventu
reduct
viral
titer
might
import
respect
provid
clue
experi
comparison
murin
defensindefici
mous
model
ryan
et
al
gounder
et
al
excess
murin
defensin
mous
model
clearli
show
protect
efficaci
beyond
natur
innat
adapt
respons
requir
excess
amount
defensin
jiang
et
al
li
et
al
sinc
adjuv
effect
depend
host
immun
system
individu
viru
type
standalon
applic
adjuvantlik
activ
defensin
apart
applic
convent
vaccin
adjuv
could
truli
broadspectrum
antivir
measur
postul
like
standalon
applic
adjuvantlik
activ
defensin
fig
one
therapeut
adjuv
concept
gounder
et
al
observ
delay
neutral
antibodi
respons
local
infect
virus
mous
model
local
murin
defensin
defici
defensin
acceler
adapt
immun
respons
may
occur
ongo
infect
concept
therapeut
adjuv
activ
defensin
line
process
natur
immun
infect
virus
howev
presenc
excess
defensin
viral
replic
may
quickli
contain
faster
mobil
adapt
immun
respons
cellmedi
innat
immun
respons
gounder
et
al
use
local
gut
paneth
cell
defici
oral
infect
mice
suggest
adjuv
role
defensin
local
impact
viral
infect
site
among
aforement
studi
exampl
lack
efficaci
therapeut
excess
suppli
primat
murin
model
kerat
brandt
et
al
exampl
efficaci
therapeut
treatment
lethal
iav
infect
mice
murin
defensin
jiang
et
al
might
consid
support
evid
concept
therapeut
adjuv
activ
defensin
experiment
neg
lack
relev
chemokin
receptor
primat
mice
posit
presenc
relev
chemokin
receptor
control
respect
studi
explor
extent
activ
defensin
ad
postinfect
acceler
mobil
adapt
immun
respons
propos
target
virus
hiv
iav
rsv
denv
might
illumin
potenti
therapeut
applic
experiment
data
suggest
scant
therapeut
adjuv
activ
defensin
set
viru
infect
lead
product
cytokin
jiang
et
al
lemessuri
et
al
sinc
increas
product
cytokin
associ
better
prognosi
recoveri
rsv
infect
seriou
problem
young
children
openshaw
openshaw
tregon
collin
melero
vivo
experi
show
protect
rsvinfect
anim
therapeut
defensin
treatment
would
especi
relev
extens
concept
therapeut
adjuv
defensinenhanc
efficaci
therapeut
antibodi
demirkhanyan
et
al
show
subinhibitori
concentr
presenc
serum
provid
modest
inhibitori
effect
hivcel
fusion
prolong
exposur
function
import
transit
epitop
cell
surfac
demirkhanyan
et
al
markedli
enhanc
viral
sensit
neutral
antibodi
aspect
defensin
implic
beyond
enhanc
efficaci
therapeut
antibodi
enhanc
immun
respons
toward
neutral
antibodi
gener
would
lead
better
uptak
antigen
neutral
epitopespecif
b
cell
receptor
bcr
bear
b
cell
enrich
b
cell
prolifer
result
better
gener
neutral
antibodi
wyke
et
al
vo
et
al
similar
aspect
defensin
activ
might
explor
target
virus
especi
neutral
epitop
flavivirus
denv
shown
reveal
molecular
breath
chang
structur
conform
viral
surfac
protein
dowd
et
al
one
challeng
denv
vaccin
develop
nonneutr
diseaseenhanc
crossreact
antibodi
respons
among
subtyp
denv
origin
antigen
sin
base
preferenti
nonneutr
crossreact
memori
respons
previous
infect
subtyp
hinder
fresh
immun
respons
neutral
epitop
newli
infect
subtyp
rothman
park
et
al
defensin
could
expos
neutral
epitop
breath
surfac
molecul
denv
neutral
epitopespecif
bcrbear
b
cell
fresh
immun
respons
might
gain
access
antigen
escap
monopol
grip
crossreact
origin
antigen
sin
studi
show
interact
human
defensin
surfac
protein
denv
howev
nglycan
envelop
glycoprotein
denv
report
crucial
dcsignmedi
infect
viru
alen
et
al
possibl
interact
surfac
glycoprotein
denv
lectinlik
human
defensin
leikina
et
al
possibl
breakthrough
result
make
test
potenti
interact
tempt
studi
rsv
regard
might
also
warrant
due
recent
studi
antibodi
recogn
prefus
conformationspecif
neutral
epitop
rsv
fusion
protein
shown
neutral
rsv
b
subgroup
mousa
et
al
case
iav
chang
glycosyl
pattern
globular
head
hemagglutinin
ha
protein
recogn
one
immun
evas
mechan
kim
et
al
tate
et
al
univers
conserv
epitop
ha
subtyp
target
univers
protect
vaccin
design
bypass
highli
variabl
immunodomin
globular
head
region
ha
major
challeng
krammer
pales
jang
seong
consid
bind
activ
lectinlik
glycoprotein
block
glycosyl
globular
head
region
defensin
enhanc
avail
subdomin
conserv
stalk
region
ha
specif
b
cell
also
tempt
possibl
anoth
possibl
use
adjuvantlik
activ
defensin
prophylact
might
provid
vaccinelik
effect
feasibl
pose
challeng
question
earlier
sinc
direct
studi
deal
likelihood
vivo
propos
framework
thought
experi
base
avail
indirect
studi
interest
prospect
emerg
put
experi
li
et
al
context
sempl
et
al
fig
reduct
lung
titer
intranas
infect
iav
intramuscular
inject
defensin
overexpress
construct
observ
li
et
al
might
consid
prophylact
system
overexpress
defensin
limit
incom
viru
replic
system
presenc
defensin
might
prime
bodi
enhanc
local
antivir
respons
defensinexacerb
virusinduc
product
type
interferon
ifn
infect
cell
plasmacytoid
dendrit
cell
pdc
might
inhibit
viral
replic
mediat
chemoattract
immun
cell
lung
antigen
present
infect
cell
remov
role
enhanc
system
basal
level
due
system
presenc
overexpress
defensin
shown
sempl
et
al
may
relev
reallif
infect
small
viral
inoculum
defensinoverexpress
mice
attain
higher
system
basal
level
debat
commens
microbi
flora
infecti
nondiseasecaus
virus
environ
possibl
play
role
rule
kernbauer
et
al
ifn
product
defensinmedi
dna
uptak
signal
tewari
et
al
may
also
sourc
elev
basal
level
ifn
result
sempl
et
al
li
et
al
translat
human
extrapol
result
might
use
vaccinelik
prophylact
applic
defensin
antivir
defens
result
sempl
et
al
recapitul
actual
rna
virus
rather
surrog
poli
c
defensinmedi
ifn
induct
rna
virus
could
appli
propos
target
virus
hiv
iav
rsv
denv
eventu
extend
virus
conceiv
shot
defensin
express
construct
could
given
prepar
flu
season
prior
travel
denvendem
area
protect
young
children
rsv
iav
caus
sever
pandem
record
histori
includ
latest
pandem
wellknown
pandem
caus
million
death
neumann
kawaoka
watanab
et
al
problem
iav
never
confid
predict
subtyp
iav
next
pandem
would
allow
preparatori
stockpil
vaccin
concept
defensin
vaccin
realiz
would
ideal
address
uncertainti
iav
rsv
shown
sensit
vesicular
stomat
viru
vsv
wellknown
ifn
sensor
ifn
produc
upon
poli
c
treatment
vitro
vivo
hill
et
al
denv
also
shown
induc
inhibit
type
ifn
kuran
enni
brass
et
al
jiang
et
al
bustosarriaga
et
al
surasombatpattana
et
al
although
virus
counterifn
measur
effici
replic
interferonpretr
cell
sittisombut
et
al
diamond
harri
haasbach
et
al
liang
et
al
wie
et
al
prophylact
defensin
vaccin
might
prime
bodi
ifnpretr
state
temporari
overexpress
defensin
mediat
exagger
viral
induct
ifn
subsequ
coantivir
activ
defensin
ifn
observ
light
clinic
practic
ifn
therapi
perri
wild
nikfar
et
al
gao
et
al
howev
ifn
therapi
use
control
ongo
fullblown
infect
defensin
vaccin
scheme
design
contain
viral
infect
initi
stage
infect
similar
vaccin
contain
cognat
viral
infect
initi
stage
mobil
memori
immun
respons
viru
one
might
ask
evolv
defensin
level
similar
prophylact
therapeut
effect
level
observ
anim
experi
hardwir
constitut
high
level
defensin
might
benefici
key
defensin
vaccin
concept
manipul
genet
program
basal
induc
level
defensin
express
provid
shot
defensin
overexpress
construct
need
would
last
limit
time
one
might
ask
human
defensin
use
standalon
adjuvantlik
activ
chemic
microbi
adjuv
product
savelkoul
et
al
greatest
advantag
human
defensin
may
peptid
enabl
us
sustain
control
product
vivo
gene
express
postul
scheme
vaccinelik
prophylact
applic
defensin
may
appear
oversimplif
admittedli
mani
leap
reason
necessit
lack
experiment
data
although
prophylact
measur
consid
better
therapeut
measur
current
dark
propos
standalon
applic
adjuvantlik
activ
defensin
like
realiz
needless
say
mani
studi
need
fill
detail
step
scheme
concret
establish
anim
experi
clinic
trial
clinic
trial
amp
divers
sourc
deriv
primarili
topic
antibacteri
antifung
purpos
yeung
et
al
fox
exist
research
gap
antibacterialantifung
antivir
applic
defensin
sinc
antivir
mechan
defensin
straightforward
antibacteri
mechan
antivir
applic
requir
system
administr
defensin
addit
basic
research
need
clinic
trial
antivir
defensin
launch
briefli
review
human
defensin
studi
antivir
applic
defensin
review
suggest
need
explor
adjuvantlik
activ
human
defensin
find
natur
level
constitut
viral
induc
defensin
provid
minim
level
defens
infect
virus
propos
prophylact
defensin
vaccin
concept
plan
control
overexpress
defensin
akin
manual
oper
safeti
lock
natur
defensin
express
program
need
propos
conceptu
line
edward
jenner
vaccin
morgan
parker
took
advantag
inher
human
immun
system
point
propos
conceptu
guidelin
studi
give
weight
either
accept
dispos
propos
